Cargando…
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report
EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730411/ https://www.ncbi.nlm.nih.gov/pubmed/36505860 http://dx.doi.org/10.3389/fonc.2022.1054593 |
_version_ | 1784845664284311552 |
---|---|
author | Wang, Huilin Yu, Qitao Shi, Lina Hou, Qinhan Dan, Liang Liang, Chuqiao Hong, Xiaoyu Zhao, Yun Ning, Ruiling |
author_facet | Wang, Huilin Yu, Qitao Shi, Lina Hou, Qinhan Dan, Liang Liang, Chuqiao Hong, Xiaoyu Zhao, Yun Ning, Ruiling |
author_sort | Wang, Huilin |
collection | PubMed |
description | EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to the combination of afatinib and chemotherapy. Identified by next-generation sequencing (NGS), EGFR G724S was found from a primary and a secondary tumor biopsy, respectively. Treated with afatinib combined with chemotherapy, both patients responded well and achieved progression-free survival. Analysis of acquired mutations developed during treatment using afatinib revealed that the emergence of EGFR T790M or ALK fusion was the potential mechanism of afatinib resistance. Our study lends credence to treatment using afatinib combined with chemotherapy as a viable option for patients with Ex19del/G724S. |
format | Online Article Text |
id | pubmed-9730411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97304112022-12-09 NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report Wang, Huilin Yu, Qitao Shi, Lina Hou, Qinhan Dan, Liang Liang, Chuqiao Hong, Xiaoyu Zhao, Yun Ning, Ruiling Front Oncol Oncology EGFR G724S mutation in exon 18 has been shown to be resistant to both first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, we found a rare mutation of EGFR Ex19del/G724S in two patients with lung cancer who demonstrated a favorable response to the combination of afatinib and chemotherapy. Identified by next-generation sequencing (NGS), EGFR G724S was found from a primary and a secondary tumor biopsy, respectively. Treated with afatinib combined with chemotherapy, both patients responded well and achieved progression-free survival. Analysis of acquired mutations developed during treatment using afatinib revealed that the emergence of EGFR T790M or ALK fusion was the potential mechanism of afatinib resistance. Our study lends credence to treatment using afatinib combined with chemotherapy as a viable option for patients with Ex19del/G724S. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9730411/ /pubmed/36505860 http://dx.doi.org/10.3389/fonc.2022.1054593 Text en Copyright © 2022 Wang, Yu, Shi, Hou, Dan, Liang, Hong, Zhao and Ning https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Huilin Yu, Qitao Shi, Lina Hou, Qinhan Dan, Liang Liang, Chuqiao Hong, Xiaoyu Zhao, Yun Ning, Ruiling NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report |
title | NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report |
title_full | NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report |
title_fullStr | NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report |
title_full_unstemmed | NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report |
title_short | NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report |
title_sort | nsclc patients with rare egfr ex19del/g724s mutation showed good response to afatinib combined with chemotherapy treatment: a two-case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730411/ https://www.ncbi.nlm.nih.gov/pubmed/36505860 http://dx.doi.org/10.3389/fonc.2022.1054593 |
work_keys_str_mv | AT wanghuilin nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT yuqitao nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT shilina nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT houqinhan nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT danliang nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT liangchuqiao nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT hongxiaoyu nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT zhaoyun nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport AT ningruiling nsclcpatientswithrareegfrex19delg724smutationshowedgoodresponsetoafatinibcombinedwithchemotherapytreatmentatwocasereport |